EGFR and prostate carcinoma: MiR-520b-3p could target epidermal growth factor receptor (EGFR), histone deacetylase 4 (HDAC4) and calpain small subunit 1 (CAPN4) respectively to exert tumor-suppressive effects in gastric cancer, lung cancer, prostate cancer [24–26].